Fig. 2From: Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinomaKaplan–Meier curves for progression-free survival (PFS) and overall survival (OS) in patients with advanced hepatocellular carcinoma who received pembrolizumab or nivolumab. (A) PFS and (B) OS.Back to article page